AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1578922 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with vincristine, prednisone, and asparaginase with triple intrathecal chemotherapy (methotrexate, hydrocortisone, cytarabine) followed by intensification with moderate‐dose MTX (Regimen A)
Number of subjects: 2404
Study 1578922 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with vincristine, prednisone, and asparaginase with triple intrathecal chemotherapy (methotrexate, hydrocortisone, cytarabine) followed by intensification with moderate‐dose MTX plus asparaginase (Regimen B)
Number of subjects: 2404
Study 1578922 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with vincristine, prednisone, and asparaginase with triple intrathecal chemotherapy (methotrexate, hydrocortisone, cytarabine) followed by intensification with moderate‐dose MTX plus cytarabine given early (Regimen C)
Number of subjects: 2404
Study 1578922 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with vincristine, prednisone, and asparaginase with triple intrathecal chemotherapy (methotrexate, hydrocortisone, cytarabine) followed by intensification with moderate‐dose MTX plus cytarabine given over the first 16 months of therapy (Regimen D)
Number of subjects: 2404
Study 1578922 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment approach for ALL
Number of subjects: 2404
Study 3001778 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg suloctidil 3-times daily
Number of subjects: 30
Study 3001778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30771333 — intervention group
Group type: COMPARATOR
Intervention: Monthly dosing of ranibizumab 0.3 mg every 4 weeks
Number of subjects: 150
Study 30771333 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat and extend without laser (TREX)
Number of subjects: 150
Study 30771333 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat and extend with navigated laser (GILA)
Number of subjects: 150
Study 28841772 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate (LC) diet
Number of subjects: 107
Study 28841772 — intervention group
Group type: COMPARATOR
Intervention: Low-Fat (LF) diet
Number of subjects: 107
Study 25577772 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite score of echocardiographic indices (derived from LV mass, LA volume, E:e', and s')
Number of subjects: 849
Study 23337366 — intervention group
Group type: EXPERIMENTAL
Intervention: elvitegravir/cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF)
Number of subjects: 708
Study 23337366 — intervention group
Group type: COMPARATOR
Intervention: ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF (ATV/RTV + FTC/TDF)
Number of subjects: 708
Study 21651419 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention program (quit the shit), 50-day intervention
Number of subjects: 1292
Study 21651419 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 1292
Study 21651419 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention program (quit the shit)
Number of subjects: 1292
Study 20088416 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 90
Study 20088416 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (Luminal 30 mg thrice daily)
Number of subjects: 90
Study 20088416 — intervention group
Group type: COMPARATOR
Intervention: Chinese medicine (herbal decoction)
Number of subjects: 90
Study 20088416 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture, Western medicine, Chinese medicine
Number of subjects: 90
Study 17955107 — intervention group
Group type: EXPERIMENTAL
Intervention: sumatriptan/naproxen sodium (85 mg sumatriptan and 500 mg naproxen sodium)
Number of subjects: 2
Study 17955107 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2
Study 17955107 — intervention group
Group type: EXPERIMENTAL
Intervention: sumatriptan
Number of subjects: 2
Study 17955107 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen sodium
Number of subjects: 2
Study 15491092 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5mg/day) with oral hygiene measures (group II)
Number of subjects: 60
Study 15491092 — intervention group
Group type: COMPARATOR
Intervention: Oral hygiene measures alone (group I)
Number of subjects: 60
Study 15001028 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral body image intervention
Number of subjects: 0
Study 15001028 — intervention group
Group type: COMPARATOR
Intervention: Brief educational session (control group)
Number of subjects: 0
Study 9860069 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) at doses of 75 or 150 mg daily
Number of subjects: 26
Study 9860069 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 26
Study 7634504 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone replacement (0.125 IU/kg/week for the first month and 0.25 IU/kg/week thereafter) for 6 months
Number of subjects: 22
Study 7634504 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone replacement for 12 months
Number of subjects: 22
Study 2571434 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (metoprolol)
Number of subjects: 0
Study 2571434 — intervention group
Group type: COMPARATOR
Intervention: Diuretics (thiazide based)
Number of subjects: 0
Study 582628 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral local anaesthetic (oxethazaine)
Number of subjects: 12
Study 582628 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkali (aluminium hydroxide and magnesium hydroxide)
Number of subjects: 12
Study 582628 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of local anaesthetic and alkali (Mucaine)
Number of subjects: 12
Study 582628 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study 31432928 — intervention group
Group type: EXPERIMENTAL
Intervention: CWA, OWA, UWA
Number of subjects: 19
Study 31432928 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 19
Study 28790224 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine-Chondroitin Sulfate (GC)
Number of subjects: 147
Study 28790224 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine-Chondroitin Sulfate-Methylsulfonylmethane (GCM)
Number of subjects: 147
Study 28790224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 26343717 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil-containing emulsion (FO)
Number of subjects: 0
Study 26343717 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil emulsion
Number of subjects: 0
Study 26343717 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 23835687 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (1.2 pmol/kg·min(‐1)) + GIP (2 pmol/kg·min(‐1))
Number of subjects: 20
Study 23835687 — intervention group
Group type: COMPARATOR
Intervention: GLP-1 (1.2 pmol/kg·min(‐1)) + 0.9% saline (Control)
Number of subjects: 20
Study 23835687 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP (2 pmol/kg·min(‐1))
Number of subjects: 20
Study 21636134 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (n=28)
Number of subjects: 49
Study 21636134 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (n=21)
Number of subjects: 49
Study 21636134 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study 18614241 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ-9
Number of subjects: 160
Study 18614241 — intervention group
Group type: EXPERIMENTAL
Intervention: EPDS
Number of subjects: 160
Study 18614241 — intervention group
Group type: EXPERIMENTAL
Intervention: SRQ-20
Number of subjects: 160
Study 16759395 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive technique using the Mayo vein stripper (Group B)
Number of subjects: 77
Study 16759395 — intervention group
Group type: COMPARATOR
Intervention: Traditional open technique (Group A)
Number of subjects: 77
Study 12525193 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by radiation therapy (arm 1)
Number of subjects: 517
Study 12525193 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy and radiation therapy (arm 2)
Number of subjects: 517
Study 12525193 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy alone (arm 3)
Number of subjects: 517
Study 12525193 — intervention group
Group type: COMPARATOR
Intervention: Overall (all arms)
Number of subjects: 517
Study 10229297 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 DM patients
Number of subjects: 20
Study 8751270 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of metronidazole (MTN), 500 mg twice a day
Number of subjects: 100
Study 8751270 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% clindamycin (CLDM) phosphate in a vaginal cream, 5 g once a day for 7 days
Number of subjects: 100
Study 1882058 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sodium fluoride solution
Number of subjects: 95
Study 1882058 — intervention group
Group type: COMPARATOR
Intervention: Placebo (deionized water)
Number of subjects: 95
Study 1882058 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (after placebo treatment)
Number of subjects: 95
Study 6979475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (dose ratio 3:2) for 14 days
Number of subjects: 28
Study 6979475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimole (dose ratio 3:2) for 14 days
Number of subjects: 28
Study 6979475 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole
Number of subjects: 28
Study 6979475 — intervention group
Group type: COMPARATOR
Intervention: Cotrimole
Number of subjects: 28
Study 3892794 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) plus Antilymphocyte globulin (ALG)
Number of subjects: 54
Study 3892794 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (MP) alone
Number of subjects: 54
Study 31446149 — intervention group
Group type: COMPARATOR
Intervention: Online Adaptive Replanning (OLAR)
Number of subjects: 21
Study 31446149 — intervention group
Group type: COMPARATOR
Intervention: Repositioning
Number of subjects: 21
Study 29683538 — intervention group
Group type: EXPERIMENTAL
Intervention: viable cryopreserved placental membrane (vCPM)
Number of subjects: 360
Study 29683538 — intervention group
Group type: COMPARATOR
Intervention: good wound care
Number of subjects: 360
Study 26297851 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal communication with black patients
Number of subjects: 33
Study 26297851 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonverbal communication with black patients
Number of subjects: 33
Study 25585479 — intervention group
Group type: EXPERIMENTAL
Intervention: Horticultural therapy intervention (HT intervention) for 16 weeks, comprising 16 weekly sessions (120 min each) at the community center and 15 minutes per day at participants' homes.
Number of subjects: 45
Study 25585479 — intervention group
Group type: EXPERIMENTAL
Intervention: Horticultural therapy intervention (HT intervention) for 16 weeks.
Number of subjects: 45
Study 22569966 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrode location at 31 mm
Number of subjects: 7
Study 22569966 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrode location at 12.6 mm (mid-region stimulation)
Number of subjects: 7
Study 22569966 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrode locations with different lengths (31, 23.8, 16.6 mm)
Number of subjects: 7
Study 22569966 — intervention group
Group type: COMPARATOR
Intervention: Electrode locations with different lengths (12.6 mm)
Number of subjects: 7
Study 20706740 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS therapy with HAN stimulation (TENStem eco), 30 min at least two times a day for 3 weeks
Number of subjects: 40
Study 20706740 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS therapy with HAN stimulation (TENStem eco)
Number of subjects: 40
Study 20706740 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 40
Study 18545115 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtendinous nailing
Number of subjects: 50
Study 18545115 — intervention group
Group type: COMPARATOR
Intervention: Paratendinous nailing
Number of subjects: 50
Study 15780457 — intervention group
Group type: EXPERIMENTAL
Intervention: Iowa Gambling Task with random number generation secondary task (executive resource loading)
Number of subjects: 0
Study 15780457 — intervention group
Group type: COMPARATOR
Intervention: Iowa Gambling Task with no secondary task
Number of subjects: 0
Study 15780457 — intervention group
Group type: EXPERIMENTAL
Intervention: Iowa Gambling Task with a secondary task that does not load executive function
Number of subjects: 0
Study 12888137 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 0
Study 12888137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10232294 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acids (9.6 g/d)
Number of subjects: 30
Study 10232294 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 30
Study 8911127 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention (weekly cognitive individual psychotherapy and bimonthly family counselling)
Number of subjects: 36
Study 8911127 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up (Control)
Number of subjects: 36
Study 2060557 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 9
Study 2060557 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 9
Study 2060557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6218583 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 60
Study 6218583 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin and aminoglycoside combination
Number of subjects: 60
Study 30563776 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg per day for 6 months
Number of subjects: 82
Study 30563776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 29494953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 27
Study 29494953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 27010235 — intervention group
Group type: EXPERIMENTAL
Intervention: Revexepride 0.02 mg
Number of subjects: 80
Study 27010235 — intervention group
Group type: EXPERIMENTAL
Intervention: Revexepride 0.1 mg
Number of subjects: 80
Study 27010235 — intervention group
Group type: EXPERIMENTAL
Intervention: Revexepride 0.5 mg
Number of subjects: 80
Study 27010235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 27010235 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (including placebo)
Number of subjects: 80
Study 24778598 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA with cuff pressure limiting 25 cmH₂O (L group)
Number of subjects: 20
Study 24778598 — intervention group
Group type: COMPARATOR
Intervention: LMA with cuff pressure limiting 60 cmH₂O (H group)
Number of subjects: 20
Study 22541443 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestion-/conditioning-enhanced placebo
Number of subjects: 17
Study 22541443 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 17
Study 19816415 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 10742
Study 18612090 — intervention group
Group type: EXPERIMENTAL
Intervention: MTCC qigong program (8 weeks)
Number of subjects: 71
Study 18612090 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 71
Study 16098116 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotène Oralbalance (OB)
Number of subjects: 20
Study 16098116 — intervention group
Group type: EXPERIMENTAL
Intervention: BioXtra (BX)
Number of subjects: 20
Study 12065273 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10770345 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 kcal daily of caloric supplement with peptides and medium-chain triglycerides plus a multivitamin and mineral supplement
Number of subjects: 536
Study 10770345 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 kcal of a caloric supplement with whole protein and long-chain triglycerides plus a multivitamin and mineral supplement
Number of subjects: 536
Study 10770345 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin and mineral supplement only
Number of subjects: 536
Study 8914032 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 409
Study 8914032 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 409
Study 1678798 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine insulin (2.5 mU.kg‐1, min‐1)
Number of subjects: 7
Study 1678798 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin (2.5 mU.kg‐1, min‐1)
Number of subjects: 7
Study 1678798 — intervention group
Group type: COMPARATOR
Intervention: Porcine insulin
Number of subjects: 7
Study 1678798 — intervention group
Group type: COMPARATOR
Intervention: Human insulin
Number of subjects: 7
Study 1678798 — intervention group
Group type: COMPARATOR
Intervention: Porcine insulin and Human insulin
Number of subjects: 7
Study 6881419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornidazole 2 g in two equal doses
Number of subjects: 72
Study 6881419 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole 2 g in two equal doses
Number of subjects: 72
Study 30326827 — intervention group
Group type: EXPERIMENTAL
Intervention: χ2‐based imbalance measures for categorical variables
Number of subjects: 0
Study 30326827 — intervention group
Group type: EXPERIMENTAL
Intervention: Area between the empirical cumulative distribution functions or the largest difference in the three pairs of quartiles
Number of subjects: 0
Study 30326827 — intervention group
Group type: EXPERIMENTAL
Intervention: (symmetrised) Kullback‐Leibler divergence
Number of subjects: 0
Study 27788949 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic nodes and prostate radiation therapy
Number of subjects: 446
Study 27788949 — intervention group
Group type: COMPARATOR
Intervention: Prostate-only radiation therapy
Number of subjects: 446
Study 27788949 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic nodes radiation therapy (in low-risk subgroup)
Number of subjects: 446
Study 27788949 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic irradiation (in patients with <15% risk of lymph node involvement)
Number of subjects: 446
Study 24576395 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate educational curriculum (n = 166)
Number of subjects: 320
Study 24576395 — intervention group
Group type: COMPARATOR
Intervention: Delayed educational curriculum (n = 154)
Number of subjects: 320
Study 22775347 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion practice (ratio of intraoperative RBC transfusion to blood loss equal to or above the median)
Number of subjects: 224
Study 22775347 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion practice (ratio of intraoperative RBC transfusion to blood loss below the median)
Number of subjects: 224
Study 22775347 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion practice
Number of subjects: 224
Study 22775347 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion practice
Number of subjects: 224
Study 19879166 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 93
Study 19879166 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery (sapheno-femoral ligation and stripping)
Number of subjects: 93
Study 17272375 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention (EI) group received a biopsychosocial treatment including cognitive behavioral skills training and biofeedback.
Number of subjects: 96
Study 17272375 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention (NI) group received treatment as usual (biopsychosocial treatment).
Number of subjects: 96
Study 16055825 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic interpersonal therapy (6 sessions)
Number of subjects: 0
Study 16055825 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 12708702 — intervention group
Group type: EXPERIMENTAL
Intervention: Small dose pulsed betamethasone therapy
Number of subjects: 0
Study 12708702 — intervention group
Group type: COMPARATOR
Intervention: Need based oral steroids
Number of subjects: 0
Study 10460365 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral CT
Number of subjects: 48
Study 10460365 — intervention group
Group type: COMPARATOR
Intervention: Sequential CT
Number of subjects: 48
Study 9097788 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular grid photocoagulation
Number of subjects: 155
Study 9097788 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 155
Study 2564772 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied tension
Number of subjects: 30
Study 2564772 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied relaxation
Number of subjects: 30
Study 2564772 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of applied tension and applied relaxation
Number of subjects: 30
Study 2564772 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 778775 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental physical therapy program
Number of subjects: 24
Study 778775 — intervention group
Group type: COMPARATOR
Intervention: Control physical therapy program
Number of subjects: 24
Study 31821506 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel, cyclophosphamide and trastuzumab
Number of subjects: 103
Study 31821506 — intervention group
Group type: COMPARATOR
Intervention: 5‐fluorouracil, epirubicin and cyclophosphamide followed by docetaxel, cyclophosphamide and trastuzumab
Number of subjects: 103
Study 31821506 — intervention group
Group type: COMPARATOR
Intervention: docetaxel, cyclophosphamide and trastuzumab followed by 5‐fluorouracil, epirubicin and cyclophosphamide
Number of subjects: 103
Study 30527595 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 106